Form 4: 4D Molecular Therapeutics CLO Exercises Options, Sells Shares

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (FDMT), engaged in transactions on November 17, 2025.
• Exercised options to acquire 1,635 shares of common stock at an exercise price of $4.14 per share.
• Immediately sold 1,635 shares of common stock at a price of $10.59 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, Mr. Bizily directly owns 3,594 shares of common stock and 75,230 stock options.
• The stock options have an exercise price of $4.14 and vest monthly over four years from March 6, 2025, with an expiration date of March 5, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While it represents a reduction in direct share ownership, it's a planned event and the officer retains a substantial number of options. The profit realized from the exercise and sale is positive for the individual.

Positives

• The officer realized a profit from exercising options and selling shares, indicating personal financial gain.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned, non-discretionary sale and can mitigate concerns about insider trading.
• The sale price of $10.59 is significantly higher than the exercise price of $4.14, demonstrating a positive return on the exercised options.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.
• The number of shares sold (1,635) represents a reduction in the officer's direct common stock holdings from 5,229 to 3,594 shares.

Future Outlook

na

Industry Context

na

Stakeholder Impact

• Shareholders: The sale by an insider could be perceived as a slight negative, but the pre-arranged nature mitigates concerns. The officer still holds significant options, aligning interests.

Next Steps

• Continued vesting of the remaining 75,230 stock options on a monthly basis from March 6, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where the Chief Legal Officer exercised stock options and sold an equivalent number of shares. Such transactions, especially when executed under a 10b5-1 plan, typically do not signal a change in the company's fundamental outlook or warrant a significant shift in investment strategy. The officer still retains a substantial number of unexercised options, maintaining alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter a prior investment thesis.

Keywords

4D Molecular Therapeutics, FDMT, Scott Bizily, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Legal Officer, Biotechnology, Pharmaceuticals